WASHINGTON--(BUSINESS WIRE)--The Biotechnology Industry Organization (BIO) opposes the Chairman’s Mark to the Medicare Prescription Drug Price Negotiation Act of 2007 (S. 3) which is being considered by the Senate Committee on Finance today.
WASHINGTON--(BUSINESS WIRE)--The Biotechnology Industry Organization (BIO) opposes the Chairman’s Mark to the Medicare Prescription Drug Price Negotiation Act of 2007 (S. 3) which is being considered by the Senate Committee on Finance today.
